N-Acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritis
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Rats with osteoarthritis induced by monoiodoacetate; numbers not stated in the abstract
- Dose used in the study
- No palmitoylethanolamide was given; the NAAA inhibitor F215 by intra-articular and intraperitoneal injection, doses not stated
- Duration
- Not stated in the abstract
- What was measured
- NAAA expression and palmitoylethanolamide levels in synovium and lumbar spinal cord; cartilage damage, synovial inflammation and pain; the effect of the PPAR-alpha antagonist MK886
What the authors reported
Osteoarthritic rats had higher NAAA and lower palmitoylethanolamide in synovium and spinal cord. F215 protected against cartilage damage and synovial inflammation by raising joint PEA levels and normalising spinal PEA, and reduced osteoarthritic pain. MK886 blocked these effects.
Limits of this study
A rat model using an enzyme inhibitor that raises the body's own PEA, not PEA supplementation; it cannot show effect in people. Doses and numbers are not in the abstract. Funding and conflicts not stated in the abstract.
Source
PubMed 31063807 · doi:10.1016/j.phrs.2019.104264
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.